Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride for hair loss increases risk of long-lasting sexual dysfunction.

Dermatologists performed the most outpatient cosmetic procedures in the U.S. from 1995 to 2003, especially on white women aged 40 to 59.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

Middle-aged patients, those in the Northeast, with comprehensive insurance, extensive hair loss, or additional health issues, and young or older females face higher alopecia areata medical costs.

Pharmacy care clinics can reduce some emergency visits by managing certain conditions and medication issues.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

Long-term effects of COVID-19 can vary over time and are more likely in certain age and gender groups, while race, income, and education levels have little to no impact. Ongoing medical care is needed due to potential complications.

Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.

Women are more likely to have long-term post-COVID symptoms than men.

Skin diseases, especially psoriasis, greatly affect people's quality of life, similar to chronic diseases.

New genetic factors linked to acne risk were discovered, highlighting the role of certain pathways and genes.

The COVID-19 pandemic led to fewer dermatology visits and changed the types of skin conditions patients experienced.

Psychological issues with skin problems worsen patients' lives and treatment.

Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.

Older age and existing health conditions increase COVID-19 death risk.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.

The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.

The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.

Darker hair colors may increase the risk of alopecia areata, while lighter hair colors may decrease it.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The meeting discussed medical findings, including benefits of certain treatments for cancer and heart conditions, and highlighted issues like poor adherence to preventive measures and skill gaps among interns.

Finasteride can cause lasting sexual dysfunction, depression, and other side effects, needing more research for treatment.

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

Women with hyperandrogenism, especially those with PCOS, are more likely to have psychiatric disorders.

People with Alopecia Areata are more likely to have autoimmune diseases, inflammatory diseases, and mental health issues like anxiety and depression.

Long-term breastfeeding and preterm labor may worsen postpartum hair loss.

Sons of mothers with polycystic ovary syndrome (PCOS) have a higher risk of obesity and insulin resistance, possibly due to certain genes and factors passed down from their mothers.

Children with atopic diseases have a higher risk of developing alopecia areata.

Females have a higher lifetime risk of alopecia areata than males.